Clinical trials: Dysthyroid Orbitopathy
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment…
- Trial name
- NCT01868997
- Testing
- teprotumumab, normal saline
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 88 people
- Sponsor
- Amgen
Safety, Tolerability
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
- Conditions
- Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
- Trial name
- NCT06569758
- Testing
- GenSci098
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Graves Ophthalmopathy
Genetics and Epigenetics of Graves' Orbitopathy
Graves' orbitopathy (GO) is an autoimmune disease persisting when immunosuppression is achieved. Orbital fibroblasts from GO patients display peculiar phenotypes even if not exposed to autoimmunity, possibly reflecting genetic or…
- Trial name
- GeneGO (NCT04488406)
- Testing
- No Intervention
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease.
- Trial name
- NCT05795621
- Testing
- IBI311
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Eye Disease
Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
Patients with Thyroid Eye Disease (TED) often have enlarged extraocular muscles and higher orbital fat contents due to their disease process.
- Trial name
- NCT01798966
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sensimed AG
Graves' Ophthalmopathy, Hypercholesterolemia
Graves' Orbitopathy and Hypercholesterolemia
The investigators have recently observed retrospectively that the occurrence of Graves' Orbitopathy in patients with Graves' disease is less frequent in patients with normal cholesterol levels, in line with another recent…
- Trial name
- GOCol (NCT02721992)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University of Pisa
Thyroid, Goiter
Subtotal Versus Total Thyroidectomy for Graves' Disease
The extent of thyroid resection in Graves' disease remains controversial. The aim of this study was to evaluate long-term results of bilateral subtotal thyroidectomy versus total thyroidectomy in patients with Graves'…
- Trial name
- NCT01408368
- Testing
- Bilateral subtotal thyroidectomy, Total thyroidectomy
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Jagiellonian University
Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
- Trial name
- NCT06248619
- Testing
- Teprotumumab
- Where
- 38 sites in United States, Argentina and 9 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Mild Graves' Ophthalmopathy
The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy
This is a prospective, randomized, double-blind, placebo-controlled study about the effect of metformin in patients with mild Graves' ophthalmopathy. Eighty patients with mild ophthalmopathy will be included.
- Trial name
- NCT02535975
- Testing
- Metformin
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Yonsei University
Graves' Ophthalmopathy
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with…
- Trial name
- NCT00430547
- Testing
- Carbimazole, radio-active iodine (I131)
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Barwon Health
Graves' Ophthalmopathy
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.
- Trial name
- NCT03922321
- Testing
- RVT-1401
- Where
- 4 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Disease
Local Triamcinolone Injection in Active Thyroid Orbitopathy
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.
- Trial name
- NCT01280214
- Testing
- Triamcinolone
- Volunteers
- 30 people
- Sponsor
- HaEmek Medical Center, Israel
Thyroid Eye Disease
Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease
To investigate corneal endothelial cell layer damage by specular microscopy in patients with thyroid eye disease
- Trial name
- NCT06235372
- Testing
- Specular microscopy
- Volunteers
- 30 people
- Sponsor
- Assiut University
Active Moderate to Severe Graves' Orbitopathy
Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients
This is a single-arm, prospective, open-label, Phase II study that explored the efficacy and safety of SHR-1314 in active moderate to severe Graves' Orbitopathy.
- Trial name
- NCT05394857
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Thyroid Associated Ophthalmopathies
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152392
- Testing
- IBI311, Follew-up
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED
This randomized controlled trial aims to compare the efficacy and safety of transconjunctival versus transcutaneous perilevator betamethasone injection in reducing upper eyelid retraction in patients with thyroid eye disease.
- Trial name
- NCT07866261
- Testing
- Betamethasone
- Volunteers
- 54 people
- Sponsor
- Assiut University
Thyroid Eye Disease
Celecoxib for Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune disorder in which the immune system attacks orbital tissues, resulting in characteristic changes in eyelid position, globe position in the orbit, extraocular muscle balance, and optic…
- Trial name
- NCT02845336
- Testing
- Celecoxib, artificial tears
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-1 (NCT07720635)
- Testing
- KHN939
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED).
- Trial name
- NCT07423013
- Testing
- [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital